Amicogen Invests in Convertible Bonds of Global Endolysin Company "Lysando"

Amicogen, a leading company in the bio-materials and pharmaceuticals sector, announced on May 9 that it has recently invested in convertible bonds (CB) worth approximately 1 billion KRW issued by Lysando AG, a global antimicrobial technology company based in Liechtenstein. With this investment, Amicogen will continue to strengthen its partnership with Lysando and maintain a foundation for collaboration in related technology fields.

Lysando AG is a German bio company recognized as a global leader in the next-generation antibiotic candidate field of "endolysin." The company currently holds more than 260 international patents and over 450 candidate substances, and is expanding its presence in the global antimicrobial market based on its proprietary technology platform.

Lysando is developing next-generation antimicrobials to combat antibiotic-resistant bacteria (superbugs) using its endolysin technology, which is derived from bacteriophage enzymes. Its flagship technology, Artilysin®, has been commercialized as a wound care medical device with European CE certification, thanks to its unique mechanism of directly breaking down the cell walls of pathogenic bacteria. Based on this, Lysando has also established global leadership in the animal and human antimicrobial markets.

In 2021, Amicogen entered into a strategic equity investment and collaboration agreement with Lysando, and has since been actively cooperating in the production of endolysin active pharmaceutical ingredients and contract development and manufacturing (CDMO) based on its protein engineering and high-efficiency fermentation process technologies. At Amicogen's Jinju production facility, endolysin is being produced using Lysando's technology, and both companies are exploring the potential for product commercialization in various application areas.

This convertible bond investment was made based on mutual trust, and both parties plan to seek medium- to long-term collaboration opportunities, including joint development and expansion of technology application areas in the future.

An Amicogen representative stated, "Lysando is a global leader with proprietary endolysin technology, as well as experience and expertise in the relevant technologies and markets. We expect that the collaboration between the two companies will make a meaningful contribution to the advancement of antimicrobial technology."

Meanwhile, Amicogen is also expanding its bio-process materials business, including resins and media, in addition to endolysin. Through continued R&D investment and global partnerships, the company is evolving into a bio-materials company focused on high value-added technologies.